What does it mean that competitive antagonism is 'surmountable'?

Because the antagonist and agonist compete for the same reversible binding site, adding enough agonist can outcompete the antagonist and restore the full maximal response; the agonist curve shifts right but its maximum is unchanged.

What does Schild analysis measure?

It uses the dose ratio (how much the agonist concentration must rise to overcome the antagonist) to estimate the antagonist's affinity, summarised as the pA2; a Schild slope near one indicates simple competitive antagonism.

Competitive Antagonists and Reversible Antagonism

A competitive antagonist binds reversibly to the same site as an agonist but has no efficacy of its own, so it produces no response and instead blocks the agonist by competition for the binding site. Its hallmark is a parallel, rightward shift of the agonist concentration-response curve that can be overcome (surmounted) by raising the agonist concentration. Schild analysis turns this shift into a quantitative estimate of the antagonist's affinity.

Definition

A competitive antagonist is a ligand that binds reversibly to the agonist's binding site with affinity but zero efficacy, reducing agonist effect by occupying receptors; because agonist and antagonist compete for the same site, the antagonism is surmountable, shifting the agonist concentration-response curve to the right in parallel without depressing its maximum.

Scope

This topic covers reversible competitive antagonism, the surmountable rightward shift of the agonist curve, the Schild equation and pA2 as measures of antagonist affinity, and the contrast with non-competitive (insurmountable) antagonism. It is a methodological reference within pharmacodynamics and does not address drug selection or dosing.

Core questions

How does a competitive antagonist reduce agonist effect without producing a response itself?
Why is competitive antagonism described as surmountable, and what does a parallel rightward shift mean?
How does Schild analysis estimate antagonist affinity from the dose ratio?
How does reversible competitive antagonism differ from non-competitive or irreversible antagonism?

Key concepts

Reversible competitive binding
Surmountable (insuperable when irreversible) antagonism
Parallel rightward shift of the agonist curve
Dose ratio
Schild equation and pA2
Zero efficacy of a neutral antagonist

Key theories

Schild analysis: Relates the dose ratio (the factor by which agonist concentration must increase to restore the original response) to antagonist concentration; the Schild plot yields the pA2, an estimate of competitive-antagonist affinity, and a slope near unity supports simple competitive antagonism.

Mechanisms

Because a competitive antagonist binds the same site as the agonist and has no efficacy, its presence lowers the proportion of receptors available to the agonist at any given agonist concentration. Increasing the agonist concentration restores occupancy and the original response, so the antagonism is surmountable and the agonist concentration-response curve is displaced to the right in parallel, with its maximum preserved. The magnitude of the shift, expressed as the dose ratio, depends only on the antagonist concentration and its affinity. Arunlakshana and Schild showed that plotting the logarithm of the dose ratio minus one against the logarithm of antagonist concentration gives a straight line whose intercept (the pA2) estimates the antagonist's equilibrium dissociation constant, provided binding is reversible and at equilibrium. If the antagonist binds effectively irreversibly or to a separate site, the maximum is depressed and the simple Schild relationship no longer holds.

Clinical relevance

Competitive, reversible blockade is the mechanism by which many receptor antagonists act, and its surmountable nature explains why their effect can in principle be overcome by higher concentrations of endogenous or exogenous agonist. This entry is reference material on how antagonism is characterised and quantified; it is not a basis for individual treatment or dosing decisions.

Evidence & guidelines

The definitions of competitive antagonist, pA2, and related affinity terms used here follow the IUPHAR recommendations on terms and symbols in quantitative pharmacology.

History

The quantitative analysis of competitive antagonism was established by Gaddum and by Schild in the mid-twentieth century, culminating in the Arunlakshana and Schild (1959) paper that introduced the dose-ratio method and the pA2 measure. Schild analysis became the standard tool for classifying antagonists and estimating their affinity, and the distinction between surmountable competitive and insurmountable non-competitive antagonism became a basic teaching of receptor pharmacology.

Key figures

Heinz Otto Schild
O. Arunlakshana
David Colquhoun
John H. Gaddum

Seminal works

arunlakshana-schild-1959
neubig-2003

Frequently asked questions

What does it mean that competitive antagonism is 'surmountable'?: Because the antagonist and agonist compete for the same reversible binding site, adding enough agonist can outcompete the antagonist and restore the full maximal response; the agonist curve shifts right but its maximum is unchanged.
What does Schild analysis measure?: It uses the dose ratio (how much the agonist concentration must rise to overcome the antagonist) to estimate the antagonist's affinity, summarised as the pA2; a Schild slope near one indicates simple competitive antagonism.